SEC Comment Letter 0000000000-23-008954 to TENAX THERAPEUTICS, INC. (TENX)

TENAX THERAPEUTICS, INC.
Date: Aug. 16, 2023 · CIK: 0000034956 · Accession: 0000000000-23-008954

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-34600

Date

August 16, 2023

Author

Christopher Giordano

Form

UPLOAD

Company

TENAX THERAPEUTICS, INC.

Letter

United States securities and exchange commission logo August 16, 2023 Christopher Giordano President and Chief Executive Officer Tenax Therapeutics, Inc. 101 Glen Lennox Drive, Suite 300 Chapel Hill, North Carolina 27517 Re:Tenax Therapeutics, Inc. Definitive Proxy Statement on Schedule 14A Filed April 28, 2023 File No. 001-34600 Dear Christopher Giordano: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Disclosure Review Program

Show Raw Text

United States securities and exchange commission logo
August 16, 2023
Christopher Giordano
President and Chief Executive Officer
Tenax Therapeutics, Inc.
101 Glen Lennox Drive, Suite 300
Chapel Hill, North Carolina 27517
Re:Tenax Therapeutics, Inc.
Definitive Proxy Statement on Schedule 14A
Filed April 28, 2023
File No. 001-34600
Dear Christopher Giordano:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Disclosure Review Program

SecProbe.io